| DC45762 |
Y-27632
Featured
|
Y-27632 is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK. |
|
| DC56000 |
AZD8154
Featured
|
AZD8154 is a highly potent, inhaled dual PI3Kγ/PI3Kδ inhibitor with pIC50 of 9.1 and 8.4, respectively. |
|
| DC56001 |
WRX606
Featured
|
WRX606 is a nonrapalog inhibitor. WRX606 formed a ternary complex with FK506-binding protein-12 (FKBP12) and FKBP−rapamycin-binding (FRB) domain of mTOR, resulting in the allosteric inhibition of mTORC1. WRX606 inhibited the phosphorylation of not only the ribosomal protein S6 kinase 1 (S6K1) but also eIF4E-binding protein-1 (4E-BP1). Hence, WRX606 efficiently suppressed tumor growth in mice without promotion of metastasis. These results suggest that WRX606 is a potent lead compound for developing anticancer drugs discovered by in silico and in cell methods. |
|
| DC60001 |
NSC45573
Featured
|
Disperse Fast Yellow 4K is a color additive used in dyes.
|
|
| DC60002 |
Piperidolate
Featured
|
Piperidolate is a tertiary amine antimuscarinic. It is similar to atropine. It is mainly used in the smooth muscle spasm of the gastrointestinal tract and inhibits intestinal cramp induced by acetylcholine in rats and dogs. |
|
| DC60003 |
MK-8719
Featured
|
MK-8719 is a highly potent and selective OGA inhibitor (EC50 = 52.7 nM) which is a Potential Treatment for Tauopathies. MK-8719 showed excellent CNS penetration that has been advanced to first-in-human phase I clinical trials. |
|
| DC60004 |
SAR-439859
Featured
|
SAR439859 is an orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD SAR439859 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells |
|
| DC60005 |
CRT0036521
Featured
|
CRT0036521 is a potent and selective inhibitor of AKR1C3. |
|
| DC60006 |
XL177A
Featured
|
XL177A is a potent USP7 inhibitor. XL177A irreversibly inhibits USP7 with sub-nM potency and selectivity across the human proteome. Evaluation of the cellular effects of XL177A reveals that selective USP7 inhibition suppresses cancer cell growth predominantly through a p53-dependent mechanism: XL177A specifically upregulates p53 transcriptional targets transcriptome-wide, hotspot mutations in TP53 but not any other genes predict response to XL177A across a panel of ~500 cancer cell lines, and TP53 knockout rescues XL177A-mediated growth suppression of TP53 wild-type (WT) cells. |
|
| DC60008 |
LY-3475070
Featured
|
LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM. LY3475070 Alone or in Combination With Pembrolizumab is now under trials for patients with Advanced Cancer. |
|
| DC60009 |
ZAP-180013
Featured
|
ZAP-180013 is a Zap70 inhibitor, which inhibits interaction with ITAMs (immunoreceptor tyrosine-based activation motifs). |
|
| DC60010 |
UUN44923
Featured
|
UUN44923 is a FTO inhibitor. UUN44923 may be useful for treating diseases assocd. with FTO targets, obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, breast cancers, small-cell lung cancers, a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma and the like. UUN44923 was reported in WO 2018157843. |
|
| DC60011 |
MK2-IN-3
Featured
|
MK2 Inhibitor III is a potent, cell-permeable inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2) and can be used for the treatment of rheumatoid arthritis. |
|
| DC60012 |
D-AP5
Featured
|
|
|
| DC60014 |
1,2-Ethanediamine, N,N-bis(2-pyridinylmethyl)-
Featured
|
|
|
| DC60016 |
NK 252
Featured
|
NK-252 is a Nrf2 activator. It acts by interacting with the Nrf2-binding site of Keap1 and downregulates the expression of fibrogenic genes. |
|
| DC60017 |
Mobocertinib (succinate)
Featured
|
Mobocertinib succinate is an investigational TKI with potent, selective preclinical activity against activating EGFR and HER2 mutations, including exon 20 insertions. TAK-788 exhibits antitumor activity in pts with EGFR exon 20 insertions with an AE profile consistent with other EGFR TKIs. |
|
| DC60018 |
5-amino-1-(4-bromophenyl)-1H-pyrazole-4-carboxylic acid
Featured
|
|
|
| DC60019 |
1H-Pyrazolo[3,4-d]pyrimidine-4,6-diamine,3-iodo-
Featured
|
|
|
| DC60020 |
Nω-Hydroxy-nor-L-Arginine Dihydrochloride
Featured
|
nor-NOHA, also known as N-Hydroxy-nor-L-Arginine, is an Arginase inhibitor. nor-NOHA induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. Nor-NOHA can induce cell apoptosis and inhibit the ability of invasion and migration of HepG2 cells by inhibiting Arg1, which is related with the increase of iNOS expression and the high concentration of NO. |
|
| DC60021 |
ML267
Featured
|
ML267 a potent Sfp phosphopantetheinyl transferase (PPTases) inhibitor with an IC50 of 0.29 μM. ML267 also inhibits AcpS-PPTase with an IC50 of 8.1 μM. ML267 possesses specific Gram-positive-targeted bactericidal activities. |
|
| DC60022 |
4(1H)-Quinazolinone, 6-chloro-2,3-dihydro-2-(1-naphthalenyl)-
Featured
|
|
|
| DC60023 |
(+)-MENTHOFURAN
Featured
|
|
|
| DC60025 |
Benzylamino tetrazine hydrochloride
Featured
|
Benzylamino tetrazine hydrochloride is a ProTAC building block. Benzylamino tetrazine hydrochloride is capable of undergoing [4+2] Diels-Alder cycloaddition reactions with strained alkenes, which makes it highly useful in bioorthogonal labeling and cell detection applications. |
|
| DC60026 |
Benzenepentanol
Featured
|
Oxyphyllacinol, also known as Benzenepentanol, is a natural product found in Alpinia oxyphylla (Yizhi) capsularfruits which are commonly used in traditional medicine. Oxyphyllacinol is an antioxidant. |
|
| DC60027 |
4-(3,4-dihydroxyphenyl)benzene-1,2-diol
Featured
|
|
|
| DC60028 |
ML251
Featured
|
ML251, a potent nanomolar T. brucei and T. cruzi phosphofructokinase (PFK) inhibitor, inhibits T. brucei PFK (IC50=0.37 μM) and T. cruzi PFK (IC50=0.13 μM). ML251 can be used for the research of parasite. |
|
| DC60029 |
Bio-Farma Bf034349
Featured
|
|
.png)
|
| DC60030 |
Tetrazine-NHBoc
Featured
|
|
|
| DC60031 |
Benzeneacetic acid, a-(phenylthio)-, ethyl ester
Featured
|
|
|
